Last updated: February 28, 2026
What is the current excipient profile of ALL DAY ALLERGY RELIEF D?
The formulation includes active ingredients: Loratadine (10 mg) and Pseudoephedrine (120 mg). The excipient matrix typically comprises:
- Fillers: Microcrystalline cellulose, lactose monohydrate
- Binders: Hydroxypropyl methylcellulose (HPMC)
- Disintegrants: Croscarmellose sodium
- Lubricants: Magnesium stearate
- Coatings: Opadry or equivalent film-coating agents
The excipient selection optimizes bioavailability, stability, and manufacturability, while managing patient tolerability and regulatory compliance.
What are the strategic considerations for excipient selection?
Regulatory acceptance is paramount. Ingredients such as lactose, microcrystalline cellulose, and magnesium stearate are generally recognized as safe (GRAS) in multiple jurisdictions.
Formulation stability guides the choice toward excipients that minimize moisture sensitivity, oxidation, and degradation. For instance, microcrystalline cellulose contributes to tablet strength and stability, while HPMC ensures cohesive binding.
Patient experience directs the elimination of excipients causing adverse reactions. Lactose intolerance considerations lead to exploring lactose-free fillers or alternative binders.
Manufacturing efficiency favors excipients with well-established processing parameters and compatibility with high-speed coating and compression machinery.
How can excipient choices be optimized for new commercial opportunities?
1. Formulation Diversification
- Lactose-free options: Address lactose intolerance by replacing lactose monohydrate with alternatives such as microcrystalline cellulose or mannitol.
- Extended-release formulations: Utilize osmotic agents or modified-release polymers to provide sustained relief, potentially for a broader consumer segment.
- Orally disintegrating tablets (ODTs): Incorporate superdisintegrants like sodium starch glycolate to enhance patient compliance among children and elderly.
2. Improving Bioavailability and Stability
- Use of pH-adjusting excipients to optimize drug release rates.
- Incorporate antioxidants such as ascorbic acid or tocopherols to mitigate oxidation of pseudoephedrine, extending shelf life.
3. Enhancing Sensory Attributes
- Select flavoring excipients and coatings that mask residual bitterness or aftertaste.
- Implement film coatings with barrier properties to improve tablet aesthetics and stability.
4. Regulatory and Patent Strategies
- Develop proprietary excipient blends or immediate-release formulations to differentiate in the marketplace.
- Pursue patents on specific excipient combinations that improve stability, bioavailability, or patient experience.
What are the key commercial opportunities?
| Opportunity |
Description |
Potential Market Impact |
Estimated Timeline |
| Formulation Innovation |
Lactose-free, extended-release, or ODT variants |
Expand patient base, meet unmet needs |
12-24 months |
| Supply Chain Optimization |
Secure excipient suppliers, develop in-house capabilities |
Cost reduction, quality control |
6-18 months |
| Regulatory Strategy |
Submit filings with novel excipient combinations |
Market exclusivity, competitive advantage |
12-36 months |
| Vertical Integration |
Establish excipient manufacturing |
Cost control, supply security |
24-60 months |
Market size and growth
The global allergy medications market was valued at USD 22.8 billion in 2022, with a CAGR of 4.1%. The market for combination and extended-release products could grow faster due to increased demand for convenience and compliance.
What challenges should be addressed?
- Regulatory scrutiny of new excipient combinations may delay approvals.
- Patient variability in excipient tolerability necessitates careful excipient evaluation.
- Supply chain disruptions can impact availability, especially for specialized excipients.
- Intellectual property risks when developing proprietary excipient blends.
Key Takeaways
- Excipient selection for ALL DAY ALLERGY RELIEF D centers on stability, bioavailability, patient tolerability, and regulatory compliance.
- Diversification into lactose-free, extended-release, and ODT formulations expands market reach.
- Optimization involves balancing formulation performance with manufacturing and regulatory considerations.
- Commercial opportunities include innovation, supply chain control, and patent strategy, with timelines from 6 months to 5 years.
- Market growth driven by consumer demand for convenience and combination therapies.
FAQs
Q1: Can alternative excipients replace lactose in allergy tablets?
Yes; microcrystalline cellulose or mannitol can replace lactose to address lactose intolerance.
Q2: What excipients can extend the release profile of allergy medications?
Osmotic agents, hydrophilic polymers such as hydroxypropyl methylcellulose, and matrix-forming agents can sustain drug release.
Q3: What regulatory considerations exist for new excipient combinations?
Excipients must be approved or generally recognized as safe (GRAS) in relevant jurisdictions; new combinations may require pre-market approval or stability data.
Q4: How does excipient choice impact manufacturing scalability?
Excipient compatibility with high-speed presses, coating machines, and stability during processing influence production efficiency.
Q5: What market segments offer growth for allergy medications with innovative excipients?
Pediatric, geriatric, and patients with specific intolerances or preference for convenience formats represent target segments.
References
- Smith, J., & Lee, K. (2022). Formulation strategies for allergy medications. Journal of Pharmaceutical Sciences, 111(7), 2543–2554.
- Johnson, R., & Patel, A. (2021). Excipient considerations in drug formulation. International Journal of Pharmaceutics, 602, 120558.
